Oncolytic vaccinia virus
AssigneeKM Biologics Co., Ltd.
InventorsToshio Murakami, Go Okita, Yui Kamizuru
Life of this patent
Estimating the term…
Loading patent…
AssigneeKM Biologics Co., Ltd.
InventorsToshio Murakami, Go Okita, Yui Kamizuru
Estimating the term…
Provided is an oncolytic virus having both improved safety and productivity. Provided are: a conditionally replicating vaccinia virus which lacks the functions of a vaccinia virus growth factor (VGF), an extracellular signal-regulated kinase (ERK) activation protein, and a ribonucleotide reductase (RNR), is not replicated in a normal cell, is selectively replicable in a proliferative cell, and has improved safety; and a conditionally replicating vaccinia virus which lacks the functions of a VGF, an ERK activation protein, and an RNR, is not replicated in a normal cell, is selectively replicable in a proliferative cell, and has improved safety and productivity, and in which a gene encoding an extracellular enveloped virus (EEV)-related protein is substituted with a gene corresponding to another vaccinia virus strain having a high EEV-producing ability.
A vaccinia virus deficient in functions of vaccinia virus growth factor (VGF), extracellular signal-regulated kinase (ERK)-activating protein, and ribonucleotide reductase (RNR), wherein all or part of regions of each of C11R, O1L, and F4L genes have been deleted or modified, and the functions of these gene products have been inactivated;
A method of improving productivity of a growth-restricted vaccinia virus, comprising:
Dependencies are inferred from the claim text.